Why the study?
In patients treated for early-stage breast cancer, long-term death more often occurs from cardiovascular diseases than cancer, necessitating strategies for prevention and comprehensive cardiovascular risk evaluation.
Comprehensive cardiovascular risk evaluation and individual clinical assessment are essential for preventing and treating cardiovascular complications in breast cancer survivors.
Supports CV risk evaluation in breast cancer survivors; leaves open optimal protocols for prospective trials.
Breast cancer (BC) is the most common malignant tumor in women. In patients who have undergone antitumor treatment at an early stage of BC, death in the long term more often occurs from cardiovascular diseases (CVD) than from cancer. Numerous studies indicate that the risk of cardiomyopathy and/or heart failure, coronary artery disease among BC survivors who received anthracyclines and/or trastuzumab is increased. Currently, early detection of cardiotoxicity using cardiac imaging and circulating cardiovascular biomarkers is widely evaluated in clinical trials. At the same time, the high risk of CVDs observed in cured breast cancer survivors is a consequence of both the adverse effects of anticancer therapy on the cardiovascular system, including antiestrogens, and the presence of common cancer and CVD risk factors. Large clinical trials reported higher rates of hypertension, hypercholesterolemia, and ischemic CVD in postmenopausal BC survivors receiving aromatase inhibitors. Strategies for the prevention and treatment of left ventricular dysfunction or heart failure in such patients should include a comprehensive cardiovascular risk evaluation and individual clinical assessment.
No takes yet. Share an insight, caveat, or question.
Мамедов et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: